YasirElaminMD

PubMed

• Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
  Sheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, Pingjun Chen, Maliazurina B Saad, Morteza Salehjahromi, John D Boom, Mohamed Qayati, James M George, Haley Allen, ...> ;Nature Communications. 2024 Apr 11
• 1 citations
  A Novel Multimodal Approach to Refractory Brain Metastases: A Case Report.
  Beckham, T., Kudchadker, R., Wefel, J., Katlowitz, K., Elamin, Y., Weinberg, J.> ;Advances in Radiation Oncology. 2024 Feb 1
• Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From-Mutant NSCLC Informs Potential Therapeutic Targets.
  Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, ...> ;JTO Clinical and Research Reports. 2024 Feb 1
• HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
  Hibiki Udagawa, Monique B Nilsson, Jacqulyne P Robichaux, Junqin He, Alissa Poteete, Hong Jiang, Simon Heeke, Yasir Y Elamin, Yuji Shibata, Shingo Matsumoto, Kiyotaka ...> ;Journal of Thoracic Oncology. 2024 Jan 1
• 1 citations
  Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
  Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, Ziping T Li, Lingzhi Hong, Natalie Vokes, Yasir Y Elamin, Celyne Bueno Hume, Ferdinandos Skoulidis, Carl M Gay, George B...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 21 citations
  Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an op...
  Joe Y Chang, Steven H Lin, Wenli Dong, Zhongxing Liao, Saumil J Gandhi, Carl M Gay, Jianjun Zhang, Stephen G Chun, Yasir Y Elamin, Frank V Fossella, George Blumenschei...> ;Lancet. 2023 Sep 9
• 3 citations
  Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-r...
  Mehmet Altan, Yan Wang, Juhee Song, James Welsh, Chad Tang, Nandita Guha-Thakurta, George R Blumenschein, Brett W Carter, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, ...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 12 citations
  Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
  Maliazurina B Saad, Lingzhi Hong, Muhammad Aminu, Natalie I Vokes, Pingjun Chen, Morteza Salehjahromi, Kang Qin, Sheeba J Sujit, Xuetao Lu, Elliana Young, Qasem Al-Tas...> ;The Lancet. Digital Health. 2023 Jul 1
• 39 citations
  Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.
  Yanshuo Chu, Enyu Dai, Yating Li, Guangchun Han, Guangsheng Pei, Davis R Ingram, Krupa Thakkar, Jiang-Jiang Qin, Minghao Dang, Xiuning Le, Can Hu, Qing Deng, Ansam Sin...> ;Nature Medicine. 2023 Jun 1
• 3 citations
  New Actions on Actionable Mutations in Lung Cancers.
  Xiuning Le, Yasir Y Elamin, Jianjun Zhang> ;Cancers. 2023 May 26
• 39 citations
  Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
  Tina Cascone, Cheuk H Leung, Annikka Weissferdt, Apar Pataer, Brett W Carter, Myrna C B Godoy, Hope Feldman, William N William Jr, Yuanxin Xi, Sreyashi Basu, Jing Jing...> ;Nature Medicine. 2023 Mar 1
• 8 citations
  Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
  Renata Ferrarotto, Luana G Sousa, Lei Feng, Frank Mott, George Blumenschein, Mehmet Altan, Diana Bell, Flavia Bonini, Kaiyi Li, Mario L Marques-Piubelli, Eduardo A Dal...> ;Journal of Clinical Oncology. 2023 May 20
• 20 citations
  CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
  Monique B Nilsson, Yan Yang, Simon Heeke, Sonia A Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y Elamin, Cesar A Moran, Yukie Kashima, Thiruvengadam Arumugam, Xiaoxing...> ;Cancer Cell. 2023 Feb 13
• 14 citations
  Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
  Lingzhi Hong, Muhammad Aminu, Shenduo Li, Xuetao Lu, Milena Petranovic, Maliazurina B Saad, Pingjun Chen, Kang Qin, Susan Varghese, Waree Rinsurongkawong, Vadeerat Rin...> ;Nature Communications. 2023 Feb 8
• 9 citations
  IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
  Sonia A Patel, Monique B Nilsson, Yan Yang, Xiuning Le, Hai T Tran, Yasir Y Elamin, Xiaoxing Yu, Fahao Zhang, Alissa Poteete, Xiaoyang Ren, Li Shen, Jing Wang, Seyed J...> ;Clinical Cancer Research. 2023 Apr 3
• 1 citations
  Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer RevealsMutations to Be Associated With Longer Overall Survival.
  Brian De, Ahsan S Farooqi, Kyle G Mitchell, Ethan B Ludmir, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, J Jack Lee, Stephen G Swisher, Don L Gibbons, ...> ;JCO Precision Oncology. 2023 Jan 1
• 4 citations
  Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
  Lingzhi Hong, Whitney E Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J Rivera, Robyn R Du, Pingjun Chen, Haley N Kemp, Waree Rinsurongkawong, Simon Heek...> ;Cancers. 2022 Jul 17
• 33 citations
  Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
  Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Hai Tran, Don L Gibbons, Simon Heeke, Frank V Fossella, Vincent K Lam, Xiuning Le, Marcelo V Negra...> ;Cancer Cell. 2022 Jul 11
• 4 citations
  Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR).
  Tahsin M Khan, Emily A Verbus, Saumil Gandhi, John V Heymach, Jonathan M Hernandez, Yasir Y Elamin> ;Annals of Surgical Oncology. 2022 Aug 1
• 38 citations
  Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
  Yasir Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo V. Negrao, Xiuning Le,...> ;Journal of Clinical Oncology. 2021 Sep 22
• 154 citations
  Structure-based classification predicts drug response in EGFR-mutant NSCLC
  Jacqulyne P. Robichaux, Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Elamin, Heather Lin, Hibiki Udagawa, Ferdinandos Skoulidis, Hai T. Tran, Susan...> ;Nature. 2021 Sep 15
• 8 citations
  Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC
  Ahsan Farooqi, Ethan B. Ludmir, Kyle G. Mitchell, Mara B. Antonoff, Chad Tang, Percy Lee, Joe Chang, Yasir Elamin, Daniel R. Gomez, Saumil Gandhi> ;Radiotherapy and Oncology. 2021 Aug 19
• 10 citations
  Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic...
  Hai T. Tran, Vincent K. Lam, Yasir Elamin, Lingzhi Hong, Rivkah Colen, Nabil Elshafeey, Islam Hassan, Mehmet Altan, George R. Blumenschein, Waree Rinsurongkawong, Melv...> ;JCO Precision Oncology. 2021 Aug 5
• 101 citations
  Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2021 Aug 1
• 13 citations
  Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
  , , , , , , , , , , , , , , , > ;Chest. 2021 Mar 1
• Join now to see all